Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis

Phase 1

• Conditions: Adenoviral Keratoconjunctivitis
• Interventions: Drug: Povidone Ophthalmic

• Registration Number: NCT04041856
• Lead Sponsor: Farabi Eye Hospital

Brief Summary

Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis

Detailed Description

Diagnosed EKC patients will be devided into two groups,first group will undergo povidone-iodine 2% eye drop four times a day and the control group will be treated only by artificial tear drops,they will be examined 3 months later and evaluations and data collections for the final comparison will be done.

Study Timeline

• Status Verified: 2019-07
• Study First Submitted: 2019-07-24
• Study First Submitted QC: 2019-07-30
• Last Update Submitted: 2019-07-30
• Study First Posted: 2019-08-01
• Last Update Posted: 2019-08-01
• Study Start: 2019-08-23
• Primary Completion: 2019-10-22
• Study Completion: 2019-11-22

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients suspected for viral conjunctivitis

Exclusion Criteria

• Allergic to iodized materials
• Age under 17

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EKC patients	Povidone Ophthalmic	Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission

Primary Outcome Measures

Name	Time	Method
Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis	3 months	Decreased patient's symptoms
Povidone-iodine 2% eye drop	3 months	Decreased viral load based on PCR results